Abstract:
The goal of this training programme was to analyse and study the developed manufacturing process for Dry powder injection of cefoperazone + Sulbactum 1.5 gm IP, a 3rd generation combination antibiotic used to treat a variety of bacterial infections including nosocomial pneumonia, intra-abdominal infections, gynaecological infections, sepsis, and others. As noted from the early evidences that cefoperazone, like all beta-lactam antibiotics, binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. While performing the inhibition mediated treatment, the molecules of cefoperazone are then attacked by enzymes such as anti-beta-lactamases, to stop the activity of cefoperazone. That’s where Sulbactum play the role of a protector for the cefoperazone molecules making the treatment more effective. The procedure began with the synthesis and purification of cefoperazone and Sulbactum, which was then combined into a single dosage form. Analytical procedures such as high-performance liquid chromatography were used to confirm the purity and identity of the medicinal component. (HPLC). The final product's physical and chemical qualities, such as dissolution rate, stability, sterility, minimum microbial count, presences of endotoxins, and other microbiological properties, were evaluated. To achieve consistency in drug quality, yield, and purity, the manufacturing process was optimised.
